Advertisement

Current Treatment Options in Allergy

, Volume 5, Issue 1, pp 118–132 | Cite as

Options in Hypersensitivity Reactions to Chemotherapeutics

  • Mauro Pagani
Drug Allergy (MJ Torres Jaén, Section Editor)
  • 43 Downloads
Part of the following topical collections:
  1. Topical Collection on Drug Allergy

Opinion statement

Purpose of review

Chemotherapeutic drugs still represent a gold standard for the treatment of neoplastic disease. They can induce hypersensitivity reactions and are the third leading cause of fatal drug-induced anaphylaxis in the USA. This article has tried to highlight and summarize the most recent scientific progress concerning risk factors, pathogenesis, diagnosis, and treatment of these reactions.

Recent findings

Identification of patients at high risk of developing hypersensitivity reactions allows risk stratification to guide clinical decision-making. Therefore, the most recent researches evaluated the possibility to perform risk stratification in case of hypersensitivity reactions to platinum compounds and taxanes. In addition, new data are now available regarding the role of in vitro test for the diagnosis of reactions to platins and the role of drug provocation test in case of hypersensitivity to a number of chemotherapeutics. However, actually, the allergological work-up includes a very careful anamnesis of the patient and the characteristics of reaction, whereas skin tests are useful only for few classes of chemotherapy, namely platinum salts and probably taxanes. Premedication, desensitization and, in some cases, skin tests are able to prevent the majority of hypersensitivity reactions, permitting the administration of the most effective therapy.

Summary

Clearly, more studies are needed to better understand, diagnose, treat, and prevent these reactions. To reach this aim, a multidisciplinar approach to the cancer patient with potential allergies is needed.

Keywords

Chemotherapy hypersensitivity Drug allergy Platinum compound hypersensitivity Taxane hypersensitivity Asparaginase hypersensitivity Desensitization 

Notes

Compliance with Ethical Standards

Conflict of Interest

Mauro Pagani declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLellan MJ. Landmark article Sept. 21, 1946: Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. By Louis S. Goodman, Maxwell M. Wintrobe, William Dameshek, Morton J. Goodman, Alfred Gilman and Margaret T. McLennan. JAMA. 1984;4(251):2255–61.CrossRefGoogle Scholar
  2. 2.
    World Health Organization available on www.who.int/cancer.
  3. 3.
    Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, et al. Clinical cancer advances 2015: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015;33:786–809.CrossRefPubMedGoogle Scholar
  4. 4.
    Donehower RC, Abeloff MD, Perry MC. Chemotherapy. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, editors. Clinical Oncology. New York: Churchill Livingstone; 1996.Google Scholar
  5. 5.
    Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999–2010: temporal patterns and demographic associations. J Allergy Clin Immunol. 2014;134:1318–1328.e7.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    RibeiroVaz I, Marques J, Demoly P, Polonia J, Gomes ER. Eur J Clin Pharmacol. 2013;69:673–81.CrossRefGoogle Scholar
  7. 7.
    Syrigou E, Syrigos K, Saif MW. Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep. 2008;8:56–62.CrossRefPubMedGoogle Scholar
  8. 8.
    Pagani M. The complex clinical picture of presumably allergic side effects cytostatic drugs: symptoms, pathomechanisms, reexposure and desensitization. Med Clin N Am. 2010;94:835–52.CrossRefPubMedGoogle Scholar
  9. 9.
    National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Published date May 28, 2009.Google Scholar
  10. 10.
    Sliesoraitis S, Chikhale PJ. Carboplatin hypersensitivity. Int J Gynecol Cancer. 2005;15:13–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol. 2003;24:253–62.CrossRefPubMedGoogle Scholar
  12. 12.
    Gadducci A, Tana R, Teti G, Zanca G, Fanucchi A, Genazzani AR. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer. 2008;18:615–20.CrossRefPubMedGoogle Scholar
  13. 13.
    Schwartz JR, Bandera C, Bradley A, Brard L, Legare R, Granai CO, et al. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience form women and infants’ Hospital. Gynecol Oncol. 2007;105:3.CrossRefGoogle Scholar
  14. 14.
    Hasan H, Shaikh OM, Rassekh SR, Howard AF, Goddart K. Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: a meta-analysis and systematic review. Pediatr Blood Cancer. 2017;64:81–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Aoyama T, Takano M, Miyamoto M, Yoshikawa T, Soyama H, Kato K, et al. Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy? Cancer Chemother Pharmacol. 2017;80:65–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Parel M, Ranchon F, Nosbaum A, You B, Vantard N, Schwiertz V, et al. Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol. 2014;15:1.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston M, et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J Cancer. 2013;109:1072–8.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hesteberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol. 2009;123:1262–1267.e1.CrossRefGoogle Scholar
  19. 19.
    • Wang AL, Patil SU, Long AA, Banerji A. Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy. Ann Allergy Asthma Immunol. 2015;115:422–8. This paper evidences the optimal treatment of patients with severe HSRs to platins.CrossRefPubMedGoogle Scholar
  20. 20.
    Wong JT, Ling M, Patil S, Banerji A, Long A. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract. 2014;2(1):40–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Lee C, Gianos M, Klausermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol. 2009;102:179–87.CrossRefPubMedGoogle Scholar
  22. 22.
    Genestreti G, di Battista M, Trisolini R, Denicolò F, Valli M, Lazzari-Agli LA, et al. A commentary on interstitial pneumonitis induced by docetaxel: clinical cases and systematic review of the literature. Tumori. 2015;101:e92–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Tracey EH, Modi B, Micheletti RG. Pemetrexed-induced pseudocellulitis reaction with eosinophilic infiltrate on skin biopsy. Am J Dermatopathol. 2017;39:e1–2.CrossRefPubMedGoogle Scholar
  24. 24.
    Forcello NP, Khubchandani S, Patel SJ, et al. Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review. J Oncol Pharm Pract. 2015 Apr;21(2):148–56.Google Scholar
  25. 25.
    Caiado J, Picard M. Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators. Curr Allergy Asthma Rep. 2014;14:451.CrossRefPubMedGoogle Scholar
  26. 26.
    • Baldo BA, Pagani M. Adverse events to non-targeted and targeted chemotherapeutic agents. Emphasis on hypersensitivity responses. Immunol Allergy Clin N Am. 2014;34:565–96. The paper highlights the most important adverse effects of chemotherapy and biologicals.CrossRefGoogle Scholar
  27. 27.
    Demoly P, Bousquet J. Drug allergy diagnosis work up. Allergy. 2002;57(Suppl 72):37–40.CrossRefPubMedGoogle Scholar
  28. 28.
    Josephs DH, Spicer JF, Corrigan CJ, et al. Epidemiological associations of allergy, IgE and cancer. Clin Exp Allergy. 2013;43:1110–23.PubMedGoogle Scholar
  29. 29.
    Popescu NA, Sheehan MG, Kouides PA, Loughner JE, Condemi JJ, Looney RJ, et al. Allergic reactions to cyclophosphamide: delayed clinical expression associated with positive immediate skin tests to drug metabolites in five patients. J Allergy Clin Immunol. 1996;97:26–33.CrossRefPubMedGoogle Scholar
  30. 30.
    Weiss RB. Hypersensitivity reactions. Semin Oncol. 1992;19:458–77.PubMedGoogle Scholar
  31. 31.
    Kuo JC, Hawkins CA, Yip D. Application of hypersensitivity skin testing in chemotherapy-induced pneumonitis. Asia Pac Allergy. 2015;5:234–6.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Dilley MA, Lee JP, Broyles A. Methotrexate hypersensitivity reactions in pediatrics: evaluation and management. Pediatr Blood Cancer. 2017;64:e26306.CrossRefGoogle Scholar
  33. 33.
    Galindo-Rodríguez G, Jaime-Pérez JC, Salinas-Carmona MC, Gonzales-Diaz SN, Castro-Corona A, Cavazos-Gonzales R, et al. Do immunoglobulin G and immunoglobulin E anti-l-asparaginase antibodies have distinct implications in children with acute lymphoblastic leukemia? A cross-sectional study. Rev Bras Hematol Hemoter. 2017;39(3):202–9.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    •• Alvarez-Cuesta E, Madrigal-Burgaleta R, Angel-Pereira D, Ureña-Tavera A, Zamora-Verduga M, Lopez-Gonzalez P, et al. Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization. Allergy. 2015;10:784–94. In this paper rhe role of drug provocation test was evaluated for the first time in a wide number of patients.CrossRefGoogle Scholar
  35. 35.
    Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52:2237–53.CrossRefPubMedGoogle Scholar
  36. 36.
    Polyzos A, Tsavaris N, Kosmos C, Arnaouti T, Kalahanis N, Tsigris C, et al. Hypersensitivity reactions to carboplatin administration are common but not always severe. A 10-year experience. Oncology. 2001;61:129–33.CrossRefPubMedGoogle Scholar
  37. 37.
    Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer. 2003;89:477–81.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005;96:824–9.CrossRefPubMedGoogle Scholar
  39. 39.
    • Giavina-Bianchi P, Patil SU, Banerji A. Immediate hypersensitivity reactions to chemotherapeutic agents. J Allergy Clin Immunol Pract. 2017;5:593–9. This paper analyzes the most recent researches about platinum and taxanes hypersensitivity.CrossRefPubMedGoogle Scholar
  40. 40.
    Castells MC. Anaphylaxis to Chemotherapy and Monoclonal Antibodies. Immunol Allergy Clin N Am. 2015;35:335–48.CrossRefGoogle Scholar
  41. 41.
    •• de Las Vecillas Sánchez L, Alenazy LA, Garcia-Neuer M, Castells MC. Drug hypersensitivity and desensitizations: mechanisms and new approaches. Int J Mol Sci. 2017;20(18):1316. This article highlights the most recent evidences concerning the mechanisms of desensitization.CrossRefGoogle Scholar
  42. 42.
    Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122:574–80.CrossRefPubMedGoogle Scholar
  43. 43.
    Patil SU, Long AA, Ling M, Wilson MT, Hesterberg P, Wong JT, et al. A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. J Allergy Clin Immunol. 2012;129(2):443–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Cernadas JC, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A, et al. General considerations on rapid desensitization for drug hypersensitivity—a consensus statement. Allergy. 2010;65:1357–66.CrossRefPubMedGoogle Scholar
  45. 45.
    Mezzano V, Gavina-Bianchi P, Picard M, Caiado J, Castells M. Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy. BioDrugs. 2014;28:133–44.CrossRefPubMedGoogle Scholar
  46. 46.
    Rosenberg B, Camp LV. The successful regression of large solid sarcoma in 180 tumors by cisplatin. Cancer Res. 1970;30:1799–802.PubMedGoogle Scholar
  47. 47.
    André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.CrossRefPubMedGoogle Scholar
  48. 48.
    Koshiba H, Hosokawa K, Kubo A, Miyagi Y, Oda T, Miyagi Y, et al. Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. Int J Gynecol Cancer. 2009;19(3):460–5.CrossRefPubMedGoogle Scholar
  49. 49.
    Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999 Apr;17(4):1141.Google Scholar
  50. 50.
    Schiavetti A, Varrasso G, Maurizi P, Castello MA. Hypersensitivity to carboplatin in children. Med Pediatr Oncol. 1999;32:183–5.CrossRefPubMedGoogle Scholar
  51. 51.
    Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. 2010;2010:1–11.Google Scholar
  52. 52.
    • Tham EH, Cheng YK, Tay MH, Alcasabas AP, Shek LP. Evaluation and management of hypersensitivity reactions to chemotherapy agents. Postgrad Med J. 2015;91(1073):145–50. Very interesting algorithm regarding the approach to the treatment of HSRs.CrossRefPubMedGoogle Scholar
  53. 53.
    Caiado J, Castells MC. Presentation and diagnosis of hypersensitivity to platinum drugs. Curr Allegy Asthma Rep. 2015;15:15.CrossRefGoogle Scholar
  54. 54.
    Masse MS, Caimmi D, Demoly P. A delayed reaction to oxaliplatin. J Investig Allergol Clin Immunol. 2012;22(5):372.3.PubMedGoogle Scholar
  55. 55.
    Otani IM, Wong J, Banerji A. Playinum chemotherapy hypersensitivity. Immunol Allergy N AM. 2017;37:663–77.CrossRefGoogle Scholar
  56. 56.
    Leguy-Seguin V, Jolimoy G, Coudert B, Pernot C, Dalac S, Vabres P, et al. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol. 2007;119(3):726–30.CrossRefPubMedGoogle Scholar
  57. 57.
    Markman M, Zanotti K, Peterson G, Webster K, Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol. 2003;15(21):4611–4.CrossRefGoogle Scholar
  58. 58.
    McAlpine JN, Kelly MG, O’malley DM, Azodi M, Coombe K, Schwartz PE, et al. Atypical presentations of carboplatin hypersensitivity reactions: characterization and management in patients with gynecologic malignancies. Gynecol Oncol. 2007;105:211–7.CrossRefPubMedGoogle Scholar
  59. 59.
    Gomez R, Harter P, Lück HJ, Traut A, Kommoss S, Kandel M, et al. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. Int J Gynecol Cancer. 2009;19(7):1284–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Pagani M, Bonadonna P. Skin test protocol for the prevention of hypersensitivity reactions to oxaliplatin. Anticancer Res. 2014;34:537–40.PubMedGoogle Scholar
  61. 61.
    Wong JT, Ling M, Patil S, Banerji A, Long A. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract. 2014;2:40–5.CrossRefPubMedGoogle Scholar
  62. 62.
    Pagani M, Venemalm L, Bonnadona P, Vescovi PP, Botelho C, Cernadas JR. An experimental biological test to diagnose hypersensitivity reactions to carboplatin: new horizons for an old problem. Jpn J Clin Oncol. 2012;42:347–50.CrossRefPubMedGoogle Scholar
  63. 63.
    Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy. 2013;68:853–61.CrossRefPubMedGoogle Scholar
  64. 64.
    • Caiado J, Venemalm L, Pereira-Santos MC, Costa L, Barbosa MP, Castells M. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract. 2013;1:494–500. Evaluate the role of in vitro tests in the diagnosis and management of HSRs to platinum compounds.CrossRefPubMedGoogle Scholar
  65. 65.
    Iwamoto T, Hirai H, Yamaguchi N, Kobayashi N, Sugimoto H, Tabata T, et al. Carboplatin-induced severe hypersensitivity reaction: role of IgE-dependent basophil activation and FceRI. Cancer Sci. 2014;105:1472–9.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Giavina-Bianchi P, Galvão VR, Picard M, Caiado J, Castells MC. Basophil activation test is a relevant biomarker of the outcome of rapid desensitization in platinum compounds-allergy. J Allergy Clin Immunol Pract. 2017;5:728–36.CrossRefPubMedGoogle Scholar
  67. 67.
    Callahan MB, Lachance JA, Stone RL, Kelsey J, Rice LW, Jazaeri AA. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol. 2007;197:199.e1–4.CrossRefGoogle Scholar
  68. 68.
    Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol. 2002 Mar;84(3):378–82.Google Scholar
  69. 69.
    Enrique E, Marek T, Castello JV, de Mateo JA. Usefulness of skin testing with platinum salts to demonstrate lack of cross-reactivity between carboplatin and cisplatin. Ann Allergy Asthma Immunol. 2008;100:86.CrossRefPubMedGoogle Scholar
  70. 70.
    Syrigou E, Makrilia N, Vassias A, Nikolaidis I, Xyla V, Manolopoulos L, et al. Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful? Anticancer Drugs. 2010;21:333–8.CrossRefPubMedGoogle Scholar
  71. 71.
    Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277:665–7.CrossRefPubMedGoogle Scholar
  72. 72.
    Alsamarai S, Sharpidod AG, Matthay RA, Confeld D, Syrigos KN, Saif MW. Pneumonitis related to docetaxel: case report and review of literature. In Vivo. 2009;23:635–7.PubMedGoogle Scholar
  73. 73.
    Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332:1004–14.CrossRefPubMedGoogle Scholar
  74. 74.
    Mertens WC, Eisenhauer EA, Jolivet J, Ernst S, Moore M, Muldal A. Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1994;5:185–7.CrossRefPubMedGoogle Scholar
  75. 75.
    Kintzel PE. Prophylaxis for paclitaxel hypersensitivity reactions. Ann Pharmacother. 2001;30:367–71.Google Scholar
  76. 76.
    Gastaminza G, de la Borbolla GM, Goikoetxea MJ, Escudero R, Antón J, Espinós J, et al. A new rapid desensitization for antineoplastic agents. J Investig Allergol Clin Immunol. 2011;21:108–12.PubMedGoogle Scholar
  77. 77.
    •• Picard M, Pur L, Caiado J, Giavina-Bianchi P, Galvão VR, Berlin ST, et al. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol. 2016;137(4):1154–64. This paper evidences the important role of skin tests in the diagnosis and risk.strtifications of patients with HSRs to taxanes.CrossRefPubMedGoogle Scholar
  78. 78.
    Chen FC, Wang LH, Zheng XY, Zhang XM, Zhang J, Li LJ. Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions. Oncotarget. 2017;8:19,236–43.Google Scholar
  79. 79.
    Berger MJ, Dunlea LJ, Rettig AE, Lustberg MB, Phillips GS, Shapiro CL. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer. 2012;20:1991–7.CrossRefPubMedGoogle Scholar
  80. 80.
    Olson JK, Sood AK, Sorosky JI, Anderson B, Buller RE. Taxol hypersensitivity: rapid retreatment is safe and cost effective. Gynecol Oncol. 1998;68:25–8.CrossRefPubMedGoogle Scholar
  81. 81.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol. 2000;18:102–5.CrossRefPubMedGoogle Scholar
  82. 82.
    Pui CK, Robinson LL, Look AT. Acute lymphoblastic leukemia. Lancet. 2008;371:1030–43.CrossRefPubMedGoogle Scholar
  83. 83.
    Woo MH, Hak LJ, Storm MC, Evans WE, Sandlund JT, Rivera GK, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia. 1998;12:1527–33.CrossRefPubMedGoogle Scholar
  84. 84.
    Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol. 2007;61:208–21.58.CrossRefPubMedGoogle Scholar
  85. 85.
    Pieters R, Hungher SP, Boos J, Rizzari C, Silverman L, Baruchel A, et al. L-asparaginase treatment in acute lymphoblastic leukemia. Focus on Erwinia asparaginase. Cancer. 2011;117:238–49.CrossRefPubMedGoogle Scholar
  86. 86.
    Vrooman LM, Supko JC, BL NDSA, Athale UH, Clavell L, et al. Erwinia aspraginase after allergy to E. coli Erwinia in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;54:199–205.PubMedPubMedCentralGoogle Scholar
  87. 87.
    • Burke MJ. How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia. Future Oncol. 2014;10:2615–27. Very exhaustive review about HSRs to asparaginase.CrossRefPubMedGoogle Scholar
  88. 88.
    Avramis VI, Avramis EV, Hunter W, Long MC. Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Anticancer Res. 2009;29:299–302.PubMedGoogle Scholar
  89. 89.
    Liu C, Kawedia JD, Cheng C, Pei D, Fernandez CA, Cai X, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia. 2012;26:2303–9.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11:1780–6.CrossRefPubMedGoogle Scholar
  91. 91.
    Soyer OU, Aytac S, Tuncer A. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia. J Allergy Clin Immunol. 2009;123:895–9.CrossRefPubMedGoogle Scholar
  92. 92.
    Akbayram S, Dogan M, Akgun Caksen H, Oner AF. A desensitization protocol in children with L-asparaginase hypersensitivity. J Pediatr Hematol Oncol. 2010;32:e187–91.CrossRefPubMedGoogle Scholar
  93. 93.
    He S, Cui Z, Wang X, Dai W, Zhang Q. Cremophor-free intravenous self-microemulsions for teniposide: safety, antitumor activity in vitro and in vivo. Int J Pharm. 2015;495:144–53.CrossRefPubMedGoogle Scholar
  94. 94.
    Sambasivan K, Mahmoud S, Kokache A, Seckl M, Savage P, et al. Hypersensitivity reactions to etoposide. J Oncol Pharm Pract. 2014;20:158–60.CrossRefPubMedGoogle Scholar
  95. 95.
    De Souza P, Friedlander M, Wilde C, Kirsten F, Ryasn M. Hypersensitivity reactions to etoposide. A report of three cases and review of the literature. Am J Clin Oncol. 1994;17:387–9.CrossRefPubMedGoogle Scholar
  96. 96.
    Hudson MM, Weinstein HJ, Donaldson SS, Greenwald C, Kun L, Tarbell NJ, et al. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin’s disease. J Clin Oncol. 1993;11:1080–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Medical Department ASST di MantovaPresidio Ospedaliero di Pieve di CorianoMantovaItaly

Personalised recommendations